Industry and Parliament Trust’s Post

The multi-stakeholder approach of EQBMED is a driver for transformative impact -- just hear from our partners. Collaborating with community and faith leaders on the ground enables a holistic partnership that supports local clinical trial sites and the needs of the community. EQBMED's trusted messengers are key to fostering trust, building sustainable partnerships, and breaking down barriers that have historically limited participation in clinical trials. Their deep community ties and knowledge help bridge the gap between science and local communities, ensuring the benefits of clinical research are available to all who wish to participate. Watch how EQBMED's ecosystem, including community leaders, biopharmaceutical industry experts from Merck and PhRMA, healthcare professionals from Medical University of South Carolina - Florence, and health advocates, work hand-in-hand to bring this work to life. https://lnkd.in/ei9wvUww

Thousands of people have now taken part in a research study supported by our Clinical Trials Accelerator Platform (CTAP). We’ve supported more than 6,000 screenings and 4,000 enrolments for CF research studies so far. Almost half of these have been in the last year alone. Read our latest blog on how UK clinical trials are growing in numbers. ➡️ https://ow.ly/u8Ck50Tjbh8 #ResearchWednesday #cysticfibrosis #clinicaltrials

🌍🔬 Celebrating International Clinical Trials Day! Every year on 20th May, we commemorate the groundbreaking work of James Lind and the ongoing efforts of various stakeholders in clinical trials across the globe- researchers, participants/patients, sponsors, regulators, academic institutes and more- who play a critical role in advancing medical science through clinical trials. At DDReg, we are committed to supporting these vital endeavors with our comprehensive regulatory services for clinical trials. From protocol development to ensuring compliance with global regulatory standards, our expertise helps streamline the clinical trial process, bringing innovative treatments to patients faster and safer. Visit our Clinical Regulatory page to know more https://lnkd.in/gQJ4xrri Join us in recognizing the importance of clinical trials including the important role of robust regulatory support in driving medical advancements forward. Let's continue to work together towards a healthier future! #InternationalClinicalTrialsDay #ClinicalTrials #RegulatoryServices #MedicalResearch #HealthcareInnovation

See you there, if you want to learn more about the myeloid cell "mess" and how to target it in fibrotic diseases.

Had a really insightful day yesterday with the CCRA https://lnkd.in/evGeaHjz Professional Awareness Update at the Royal Society of Medicine. There’s always something to learn, and this time we learned, from Andrea Manfrin PhD MBA PharmD - the incredible achievements of the MHRA in the last 12 months! - the backlog has been cleared and all pre-Covid targets are surpassed - the average time to trial approval is 29 days! - that the UK is now No4 in the global rankings for Phase II Trials - We also discussed the role of @MHRA in investigations for Medical Devices Mark Grumbridge CSci MTOPRA - Equity in clinical research (and needs/merits) Ameeta Retzer - FDA guidance, cutting edge Decentralised clinical trials & inSilico trials Graham Wylie Prof Alejandro Frangi FREng Amazing. Is your clinical partner’s knowledge right up-to-date?? In the Christmas spirit, finished of with a glass of wine round the corner 🥂🍷 https://lnkd.in/eHNeQb9a

🧨 The Year starts with some good news - together with Łukasz Izbicki, PharmD, PhD we will talk at EUCROF 2025 Conference in Copenhagen 3-4.02.2025 about Enhancing Accessibility to Clinical Trials in Europe, using our platform ClinicalTrials.EU. After one year since the start of it, it is high time to address barriers in trials visibility and access, showcase our progress and talk about the future of clinical trials in EU. Will YOU be there to discuss it with us? 💙 #EUCROF #clinicalresearch #clinicaltrials #clinicaloperations #gcp #bigpharma #dct #EUCROF25  

On May 20th, we are honoring 🎉 International Clinical Trials Day, a day dedicated to raising awareness 📢 and recognizing the tireless efforts of everyone involved in clinical trials. This date pays tribute to one of the first randomized clinical trials, initiated on the same day in 1747 by James Lind (1716–1794). Representing 10 statistical associations across Europe, we at #EFSPI are committed to maintaining professional statistical standards, especially in the context of clinical trials and their methodologies. Quantitative decision-making is an integral part of clinical trials, but the quality of the analysis and interpretation of the evidence are directly tied to the quality of the data. Healthcare professionals, researchers, and all staff at clinical trial facilities work tirelessly each day to gather and provide high-quality data that meets the objectives set out in the clinical trial protocol. Their role is fundamental in the process, often undertaken in demanding circumstances. We also want to acknowledge the patients who participate in these trials. Their trust, courage and resilience are vital to the progression of medical science. Their participation in clinical trials paves the way for improved treatments and therapies, ultimately enhancing patient care worldwide. We invite you to take a moment to reflect on the importance of clinical trials and express your gratitude for those who dedicate their days to this important work. Their contributions are key to improving patient outcomes. 🙏 #ClinicalTrialsDay #collaboration #gratitude

New trade association sets sights on advancing multisite clinical research corporations https://lnkd.in/gpjPVizf As multisite clinical research corporations (MCRCs) proliferate to meet the increased demand for larger clinical trials that span the globe, they’ll have a new trade association to back them up. The Association of Multisite Research [...]

The ability to confirm a research participants eligibility for a clinical trial based on their current and/or past research history has been a gap in our industry. Verified Clinical Trials was initially built to prevent single study & cross-sponsor duplicate & professional participants from entering clinical trials, but we have developed our capabilities into much more than that. For example, in many of the clinical trials, within the exclusion criteria, it mentions a participant must be naive to the compound. By using VCT to support a Ph1 and/or Ph2, we have the ability to make sure a participant enrolled in the Ph2 cannot enroll in the Ph3. Without VCT, there is no other way to prevent a participant who has enrolled in the Ph2 from enrolling in the Ph3. This is 1 of many protocol violations we prevent (at screening!). Let's collaborate to ensure you're enrolling the most qualified research participants possible as these additional insights and transparency will pay dividends in the long run.

Even after 40 years of clinical research, sites aren't always sure that sponsors and CROs understand what benefits they need from the partnership. If you're attending SCOPE, join the panel discussion, "What Sites Really Want from Study Sponsors and CROs," on Wed, Feb 5th, at 8:55am, to hear from representatives at leading sites, including Lauren Chazal, M.B.A., our Chief Business Development Officer at Headlands Research, about what their organizations really want from sponsors and CROs. #SCOPEsummit #SiteSolutions #ClinicalTrialSites #HeadlandsResearch https://lnkd.in/e3eMJDks